BibSonomy :: publication ::

tag user group author concept BibTeX key search:all search:hruehs

The blue social bookmark and publication sharing system.

entry of hruehs:

(0)

This publication has not been reviewed yet.

rating distribution

average user rating

The average rating is computed over all reviews. However, some of them may be invisible to you due to the visibility setting chosen by the reviewers.

(0.0 of 5.0 based on 0 reviews)

Pharmacokinetics and Pharmacodynamics of Oral Etoposide in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia

by: Mathew J. Edick, Amar Gajjar, Hazem H. Mahmoud, Matthijs E. C. van de Poll, Patricia L. Harrison, John C. Panetta, Gaston K. Rivera, Raul C. Ribeiro, John T. Sandlund, James M. Boyett, Ching-Hon Pui, and Mary V. Relling

In: J Clin Oncol, Vol. 21, Nr. 7 (2003) , p. 1340-1346.

Abstract

Purpose: To study the pharmacokinetics and pharmacodynamics of once- versus twice-daily oral etoposide in children with relapsed or refractory acute lymphoblastic leukemia ALL. Patients and Methods: Fifty-eight patients were randomly assigned to etoposide at 50 mg/m2/d with once- versus twice-daily doses for 22 days. On day 8, vincristine, asparaginase, and dexamethasone were started. Etoposide pharmacokinetics and pharmacodynamics were studied for 47, 28, and 26 patients on day 1, 8, and 22, respectively, of remission reinduction therapy. Results: Of 48 patients with pharmacokinetic data, 42 87.5% achieved complete remission, three 6.3% failed to achieve remission, and three 6.3% died during induction. Median etoposide day 8 area under concentration-time curve AUC and cumulative AUC tended to be greater P = .06 and P = .07, respectively in patients n = 23 who achieved complete remission 24 and 522 micromol/L * h, respectively than in patients n = 3 who did not 14

BibTeX record

@article{Edick.2003,
  abstract = {Purpose: To study the pharmacokinetics and pharmacodynamics of once- versus twice-daily oral etoposide in children with relapsed or refractory acute lymphoblastic leukemia (ALL). Patients and Methods: Fifty-eight patients were randomly assigned to etoposide at 50 mg/m2/d with once- versus twice-daily doses for 22 days. On day 8, vincristine, asparaginase, and dexamethasone were started. Etoposide pharmacokinetics and pharmacodynamics were studied for 47, 28, and 26 patients on day 1, 8, and 22, respectively, of remission reinduction therapy. Results: Of 48 patients with pharmacokinetic data, 42 (87.5%) achieved complete remission, three (6.3%) failed to achieve remission, and three (6.3%) died during induction. Median etoposide day 8 area under concentration-time curve (AUC) and cumulative AUC tended to be greater (P = .06 and P = .07, respectively) in patients (n = 23) who achieved complete remission (24 and 522 {micro}mol/L * h, respectively) than in patients (n = 3) who did not (14 },
  added-at = {2010-02-04T16:31:48.000+0100},
  author = {Edick, Mathew J. and Gajjar, Amar and Mahmoud, Hazem H. and van de Poll, Matthijs E. C. and Harrison, Patricia L. and Panetta, John C. and Rivera, Gaston K. and Ribeiro, Raul C. and Sandlund, John T. and Boyett, James M. and Pui, Ching-Hon and Relling, Mary V.},
  biburl = {http://www.bibsonomy.org/bibtex/28aa5ebb3e255d5d8291bc0bbc7879003/hruehs},
  interhash = {0b0ad5305d1018699bbcbd416d83d7ef},
  intrahash = {8aa5ebb3e255d5d8291bc0bbc7879003},
  journal = {J Clin Oncol},
  keywords = {imported},
  number = 7,
  pages = {1340-1346},
  timestamp = {2010-02-04T16:31:48.000+0100},
  title = {Pharmacokinetics and Pharmacodynamics of Oral Etoposide in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia},
  volume = 21,
  year = 2003
}

Endnote record

%0 Journal Article
%1 Edick.2003
%A Edick, Mathew J.
%A Gajjar, Amar
%A Mahmoud, Hazem H.
%A van de Poll, Matthijs E. C.
%A Harrison, Patricia L.
%A Panetta, John C.
%A Rivera, Gaston K.
%A Ribeiro, Raul C.
%A Sandlund, John T.
%A Boyett, James M.
%A Pui, Ching-Hon
%A Relling, Mary V.
%D 2003
%J J Clin Oncol
%K 
%N 7
%P 1340-1346
%T Pharmacokinetics and Pharmacodynamics of Oral Etoposide in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia
%V 21
%X Purpose: To study the pharmacokinetics and pharmacodynamics of once- versus twice-daily oral etoposide in children with relapsed or refractory acute lymphoblastic leukemia (ALL). Patients and Methods: Fifty-eight patients were randomly assigned to etoposide at 50 mg/m2/d with once- versus twice-daily doses for 22 days. On day 8, vincristine, asparaginase, and dexamethasone were started. Etoposide pharmacokinetics and pharmacodynamics were studied for 47, 28, and 26 patients on day 1, 8, and 22, respectively, of remission reinduction therapy. Results: Of 48 patients with pharmacokinetic data, 42 (87.5%) achieved complete remission, three (6.3%) failed to achieve remission, and three (6.3%) died during induction. Median etoposide day 8 area under concentration-time curve (AUC) and cumulative AUC tended to be greater (P = .06 and P = .07, respectively) in patients (n = 23) who achieved complete remission (24 and 522 {micro}mol/L * h, respectively) than in patients (n = 3) who did not (14